Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour

Jen Chieh Lee, Yung Ming Jeng, Sheng Yao Su, Chen Tu Wu, Keh Sung Tsai, Cheng Han Lee, Chung Yen Lin, Jodi M. Carter, Jenq Wen Huang, Shu Hwa Chen, Shyang Rong Shih, Adrián Mariño-Enríquez, Chih Chi Chen, Andrew L. Folpe, Yih Leong Chang, Cher Wei Liang

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Phosphaturic mesenchymal tumours (PMTs) are uncommon soft tissue and bone tumours that typically cause hypophosphataemia and tumour-induced osteomalacia (TIO) through secretion of phosphatonins including fibroblast growth factor 23 (FGF23). PMT has recently been accepted by the World Health Organization as a formal tumour entity. The genetic basis and oncogenic pathways underlying its tumourigenesis remain obscure. In this study, we identified a novel FN1-FGFR1 fusion gene in three out of four PMTs by next-generation RNA sequencing. The fusion transcripts and proteins were subsequently confirmed with RT-PCR and western blotting. Fluorescence in situ hybridization analysis showed six cases with FN1-FGFR1 fusion out of an additional 11 PMTs. Overall, nine out of 15 PMTs (60%) harboured this fusion. The FN1 gene possibly provides its constitutively active promoter and the encoded protein's oligomerization domains to overexpress and facilitate the activation of the FGFR1 kinase domain. Interestingly, unlike the prototypical leukaemia-inducing FGFR1 fusion genes, which are ligand-independent, the FN1-FGFR1 chimeric protein was predicted to preserve its ligand-binding domains, suggesting an advantage of the presence of its ligands (such as FGF23 secreted at high levels by the tumour) in the activation of the chimeric receptor tyrosine kinase, thus effecting an autocrine or a paracrine mechanism of tumourigenesis.

Original languageEnglish
Pages (from-to)539-545
Number of pages7
JournalJournal of Pathology
Volume235
Issue number4
DOIs
Publication statusPublished - Mar 1 2015
Externally publishedYes

Fingerprint

Neoplasms
Gene Fusion
Ligands
Receptor, Fibroblast Growth Factor, Type 1
RNA Sequence Analysis
Receptor Protein-Tyrosine Kinases
Fluorescence In Situ Hybridization
Leukemia
Phosphotransferases
Western Blotting
Bone and Bones
Polymerase Chain Reaction
Genes
Proteins
fibroblast growth factor 23

Keywords

  • FGFR1
  • FN1
  • Phosphaturic mesenchymal tumour
  • RNA sequencing
  • Translocation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lee, J. C., Jeng, Y. M., Su, S. Y., Wu, C. T., Tsai, K. S., Lee, C. H., ... Liang, C. W. (2015). Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. Journal of Pathology, 235(4), 539-545. https://doi.org/10.1002/path.4465

Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. / Lee, Jen Chieh; Jeng, Yung Ming; Su, Sheng Yao; Wu, Chen Tu; Tsai, Keh Sung; Lee, Cheng Han; Lin, Chung Yen; Carter, Jodi M.; Huang, Jenq Wen; Chen, Shu Hwa; Shih, Shyang Rong; Mariño-Enríquez, Adrián; Chen, Chih Chi; Folpe, Andrew L.; Chang, Yih Leong; Liang, Cher Wei.

In: Journal of Pathology, Vol. 235, No. 4, 01.03.2015, p. 539-545.

Research output: Contribution to journalArticle

Lee, JC, Jeng, YM, Su, SY, Wu, CT, Tsai, KS, Lee, CH, Lin, CY, Carter, JM, Huang, JW, Chen, SH, Shih, SR, Mariño-Enríquez, A, Chen, CC, Folpe, AL, Chang, YL & Liang, CW 2015, 'Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour', Journal of Pathology, vol. 235, no. 4, pp. 539-545. https://doi.org/10.1002/path.4465
Lee, Jen Chieh ; Jeng, Yung Ming ; Su, Sheng Yao ; Wu, Chen Tu ; Tsai, Keh Sung ; Lee, Cheng Han ; Lin, Chung Yen ; Carter, Jodi M. ; Huang, Jenq Wen ; Chen, Shu Hwa ; Shih, Shyang Rong ; Mariño-Enríquez, Adrián ; Chen, Chih Chi ; Folpe, Andrew L. ; Chang, Yih Leong ; Liang, Cher Wei. / Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. In: Journal of Pathology. 2015 ; Vol. 235, No. 4. pp. 539-545.
@article{f5de6667ca404ec3864558349a7224e1,
title = "Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour",
abstract = "Phosphaturic mesenchymal tumours (PMTs) are uncommon soft tissue and bone tumours that typically cause hypophosphataemia and tumour-induced osteomalacia (TIO) through secretion of phosphatonins including fibroblast growth factor 23 (FGF23). PMT has recently been accepted by the World Health Organization as a formal tumour entity. The genetic basis and oncogenic pathways underlying its tumourigenesis remain obscure. In this study, we identified a novel FN1-FGFR1 fusion gene in three out of four PMTs by next-generation RNA sequencing. The fusion transcripts and proteins were subsequently confirmed with RT-PCR and western blotting. Fluorescence in situ hybridization analysis showed six cases with FN1-FGFR1 fusion out of an additional 11 PMTs. Overall, nine out of 15 PMTs (60{\%}) harboured this fusion. The FN1 gene possibly provides its constitutively active promoter and the encoded protein's oligomerization domains to overexpress and facilitate the activation of the FGFR1 kinase domain. Interestingly, unlike the prototypical leukaemia-inducing FGFR1 fusion genes, which are ligand-independent, the FN1-FGFR1 chimeric protein was predicted to preserve its ligand-binding domains, suggesting an advantage of the presence of its ligands (such as FGF23 secreted at high levels by the tumour) in the activation of the chimeric receptor tyrosine kinase, thus effecting an autocrine or a paracrine mechanism of tumourigenesis.",
keywords = "FGFR1, FN1, Phosphaturic mesenchymal tumour, RNA sequencing, Translocation",
author = "Lee, {Jen Chieh} and Jeng, {Yung Ming} and Su, {Sheng Yao} and Wu, {Chen Tu} and Tsai, {Keh Sung} and Lee, {Cheng Han} and Lin, {Chung Yen} and Carter, {Jodi M.} and Huang, {Jenq Wen} and Chen, {Shu Hwa} and Shih, {Shyang Rong} and Adri{\'a}n Mari{\~n}o-Enr{\'i}quez and Chen, {Chih Chi} and Folpe, {Andrew L.} and Chang, {Yih Leong} and Liang, {Cher Wei}",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/path.4465",
language = "English",
volume = "235",
pages = "539--545",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour

AU - Lee, Jen Chieh

AU - Jeng, Yung Ming

AU - Su, Sheng Yao

AU - Wu, Chen Tu

AU - Tsai, Keh Sung

AU - Lee, Cheng Han

AU - Lin, Chung Yen

AU - Carter, Jodi M.

AU - Huang, Jenq Wen

AU - Chen, Shu Hwa

AU - Shih, Shyang Rong

AU - Mariño-Enríquez, Adrián

AU - Chen, Chih Chi

AU - Folpe, Andrew L.

AU - Chang, Yih Leong

AU - Liang, Cher Wei

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Phosphaturic mesenchymal tumours (PMTs) are uncommon soft tissue and bone tumours that typically cause hypophosphataemia and tumour-induced osteomalacia (TIO) through secretion of phosphatonins including fibroblast growth factor 23 (FGF23). PMT has recently been accepted by the World Health Organization as a formal tumour entity. The genetic basis and oncogenic pathways underlying its tumourigenesis remain obscure. In this study, we identified a novel FN1-FGFR1 fusion gene in three out of four PMTs by next-generation RNA sequencing. The fusion transcripts and proteins were subsequently confirmed with RT-PCR and western blotting. Fluorescence in situ hybridization analysis showed six cases with FN1-FGFR1 fusion out of an additional 11 PMTs. Overall, nine out of 15 PMTs (60%) harboured this fusion. The FN1 gene possibly provides its constitutively active promoter and the encoded protein's oligomerization domains to overexpress and facilitate the activation of the FGFR1 kinase domain. Interestingly, unlike the prototypical leukaemia-inducing FGFR1 fusion genes, which are ligand-independent, the FN1-FGFR1 chimeric protein was predicted to preserve its ligand-binding domains, suggesting an advantage of the presence of its ligands (such as FGF23 secreted at high levels by the tumour) in the activation of the chimeric receptor tyrosine kinase, thus effecting an autocrine or a paracrine mechanism of tumourigenesis.

AB - Phosphaturic mesenchymal tumours (PMTs) are uncommon soft tissue and bone tumours that typically cause hypophosphataemia and tumour-induced osteomalacia (TIO) through secretion of phosphatonins including fibroblast growth factor 23 (FGF23). PMT has recently been accepted by the World Health Organization as a formal tumour entity. The genetic basis and oncogenic pathways underlying its tumourigenesis remain obscure. In this study, we identified a novel FN1-FGFR1 fusion gene in three out of four PMTs by next-generation RNA sequencing. The fusion transcripts and proteins were subsequently confirmed with RT-PCR and western blotting. Fluorescence in situ hybridization analysis showed six cases with FN1-FGFR1 fusion out of an additional 11 PMTs. Overall, nine out of 15 PMTs (60%) harboured this fusion. The FN1 gene possibly provides its constitutively active promoter and the encoded protein's oligomerization domains to overexpress and facilitate the activation of the FGFR1 kinase domain. Interestingly, unlike the prototypical leukaemia-inducing FGFR1 fusion genes, which are ligand-independent, the FN1-FGFR1 chimeric protein was predicted to preserve its ligand-binding domains, suggesting an advantage of the presence of its ligands (such as FGF23 secreted at high levels by the tumour) in the activation of the chimeric receptor tyrosine kinase, thus effecting an autocrine or a paracrine mechanism of tumourigenesis.

KW - FGFR1

KW - FN1

KW - Phosphaturic mesenchymal tumour

KW - RNA sequencing

KW - Translocation

UR - http://www.scopus.com/inward/record.url?scp=84922647170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922647170&partnerID=8YFLogxK

U2 - 10.1002/path.4465

DO - 10.1002/path.4465

M3 - Article

C2 - 25319834

AN - SCOPUS:84922647170

VL - 235

SP - 539

EP - 545

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -